Spanish pharmaceutical companies do not come out unscathed on the stock exchange. In a quarter in which the Ibex35 rebounded 6.6% to close the session on June 30th with 7,231 points, compared to 6,785 points on March 31st, Spanish pharmaceutical companies fell by 2.7% on the trading floor. The aggregate market capitalization of the six listed Spanish pharma companies on June 30th, was $20.2 billion (€17.95 billion), compared to $20.8 billion (€18.45 billion) in the previous quarter.
Read more about the latest available financial results of the six listed Spanish pharma companies and find the most interesting business news with the Born2Invest mobile app.
The only pharmaceutical company that has dragged its feet in the sector is Grifols
The largest by capitalization, Grifols’ shares have contracted by more than 12%. The plasma derivatives giant closed the quarter with a 12.8% fall on the stock market, with a market capitalization of $13 million (€11.52 million), far from the second largest company in terms of capitalization, which is Almirall, with $2.3 million (€2.04 million). The worst record came on June 4th, when the price per share stood at $30.6 (€27.1).
According to the latest available results, Grifols closed the first quarter of 2020 with a turnover of $1.46 million (€1.29 million), an increase of 11.8% compared to the same period in 2018. Grifols ended the quarter with a 12.8% fall in the stock market, with a market capitalization of $13 million(€11.51 million).
The company, which has been working for months on a compound to address COVID-19, closed the session with a price of $8.6 (€7.6) per share, a rise of 74.7%. The Spanish pharmaceutical company closed the first quarter of 2020 with a net profit of $79.9 million (€70.6 million), compared with a loss of $11.7 million (€10.4 million) in 2019. In addition, the company achieved total sales revenue during the first quarter of 2020 of $28 million (€24.8 million).
For their part, the shares of the Reig Jofre family multinational, which specializes in generic drugs with a focus on beta-lactam antibiotics and lyophilized injectables, increased to $3.5 (€3.1) per share, a 59% increase over the previous quarter. Last week, it was revealed that the company plans to produce 700 million doses of coronavirus vaccine per year. At full capacity, Reig Jofre expects to fill between one and two million vials a day.
The most moderate growth was for Faes Farma
As for Rovi, shares rose by 11.4% at the end of June to $28.5 (€25.3) per share. The pharmaceutical company, which reported net income of $15.7 million (€13.9 million) in the first quarter of this year, double the figure for the same period in 2019, is working with HM Hospitales to develop a clinical trial for Covid-19.
The shares of Almax’s owner group, Almirall, increased to $13.2 (€11.7) per share at the end of the second quarter of the year, 11.2% more than in the previous quarter. The company announced its jump to the Ibex35 at the beginning of June, filling the vacancy left by the Mediaset communications group.
The most moderate growth was registered by Faes Farma. The company closed the quarter with a 2.2% rise on the stock market, with a market capitalization of $1.16 million (€1.03 million). The Spanish pharmaceutical company achieved a net profit of $23.5 million (€20.8 million) between January and March 2020, which represents an increase of 27.3% with respect to the same quarter of the previous year.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Increase in Airport Opportunities Mirrors Rebounding Passenger Travel
The conference focused on collaborative efforts by public owners, private sector investors, and contractors. Experts were on hand to discuss...
BlackRock Launches First Liquid ESG Equity Alternative Fund in Europe
The Systematic ESG Equity Absolute Return Fund (SEEAR) alunched by BlackRock is designed for Liquid Alternatives investors seeking a global...
El Cesar has the Conditions to Enter the Medical Cannabis Market in Colombia
Municipalities such as San Alberto, San Martin, Gonzalez, among others, have the conditions to grow medical cannabis, a bet of...
Analysts Forecast a Bitcoin Price Between $51,000 and $1 Million
if you look at the Bitcoin price forecasts of other well-known faces from the crypto industry, Alfred is not alone...
Forget Facebook (NASDAQ: FB) and Apple (NASDAQ: AAPL): Virtual Reality (VR) and Augmented Reality (AR) Investors Should Snap Up XRApplied (CSE: XRA) Instead
It’s no secret that AR, VR, and MR are hot investments right now. Facebook’s throwing the weight of 10,000 full-time...
Business6 days ago
Nine Ways to Make Your Blog More Engaging
Biotech5 days ago
Claris Ventures, €85 Million Closing for the Turin-based Sgr Focused on Early-Stage Biotech
Featured4 days ago
Why Gold Continues to Struggle
Business4 days ago
Is Augmented Reality (AR) the Best Thing to Happen to Education? Yes, it is!